173 related articles for article (PubMed ID: 26265211)
1. Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.
Afghahi A; Forgó E; Mitani AA; Desai M; Varma S; Seto T; Rigdon J; Jensen KC; Troxell ML; Gomez SL; Das AK; Beck AH; Kurian AW; West RB
Breast Cancer Res; 2015 Aug; 17(1):108. PubMed ID: 26265211
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of ductal carcinoma in situ and association with progression.
Lin CY; Vennam S; Purington N; Lin E; Varma S; Han S; Desa M; Seto T; Wang NJ; Stehr H; Troxell ML; Kurian AW; West RB
Breast Cancer Res Treat; 2019 Nov; 178(2):307-316. PubMed ID: 31420779
[TBL] [Abstract][Full Text] [Related]
3. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
5. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
6. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
7. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
8. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
9. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
10. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
[TBL] [Abstract][Full Text] [Related]
11. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
[TBL] [Abstract][Full Text] [Related]
12. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
[TBL] [Abstract][Full Text] [Related]
13. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
14. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
15. Progression Potential of Ductal Carcinoma in situ Assessed by Genomic Copy Number Profiling.
Kitamura M; Nakayama T; Mukaisho KI; Mori T; Umeda T; Moritani S; Kushima R; Tani M; Sugihara H
Pathobiology; 2019; 86(2-3):92-101. PubMed ID: 30332671
[TBL] [Abstract][Full Text] [Related]
16. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
[TBL] [Abstract][Full Text] [Related]
17. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
18. Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.
Liao S; Desouki MM; Gaile DP; Shepherd L; Nowak NJ; Conroy J; Barry WT; Geradts J
Genes Chromosomes Cancer; 2012 Dec; 51(12):1067-78. PubMed ID: 22887771
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
20. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
Rane SU; Mirza H; Grigoriadis A; Pinder SE
Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]